Testimonials From Pharma-Biotech Product & Company Valuation
Very well organised, useful (concise) course material with practical examples.
EvaluateKaren Siriwardana, Senior Analyst - United Kingdom - March 2018
Very insightful! Great breakdown of different perspectives of valuation!
Cura Innova VenturesKenneth Fernald, Partner - The Netherlands - March 2018
Fantastic intro from a valuation veteran!
Eurofins BioPharma Product TestingMarcel Langoor, Director Business Development - The Netherlands - March 2018
Course was excellent. Patrik was very knowledgeable and I feel has given me a good platform to build upon creating my own valuation models.
EvaluateNick Cattle, Senior Analyst - United Kingdom - March 2018
It’s a useful course to get an understanding of the frameworks being applied to valuating products, companies & deals.
Numab TherapeuticsRoland Helfenstein, Chief Financial Officer - Switzerland - November 2017
This course gives very valuable valuation tools and understanding of value drivers and practitioner's knowledge of what assumptions are used in valuation. Moreover, it is very clear and understandable.
Vistula BioventureAnna Rzewuska, Managing Partner - Poland - November 2017
Excellent content and relevant info. Great course overall!
Oxford PharmascienceChris Hill, Chief Financial Officer - United Kingdom - November 2017
Very good in concept and presentation. The case studies are excellent!
Topadur PharmaMarkus Ducrey, Finance/Strategy - Switzerland - November 2017
Very well-structured, easy-to-follow and thorough introduction to Valuation - as seen from different perspectives.
ImmaticsAjla Hrle, BD Manager - Germany - March 2017
Going in with some valuation experience, this course is great for considering different approaches to supplement your current valuation methods. Would highly recommend!
AlacritaSaadia Basharat, Consultant - United Kingdom - March 2017
Good validation of present day tools and structure in valuing products and companies.
Echelon-Frontier ScientificTim Miller, CEO and President - USA - March 2017
A great course packed with useful tools in assessing and valuating biotech companies and products.
Medeon Science Park & IncubatorUlf G Andersson, CEO - Sweden - March 2017
Patrik’s course is a very good general introduction to company and product valuations in the field of life science, with great examples and material. I particularly liked the module on structuring a licensing deal. You can easily tell that Patrik has a vast experience in the field of valuation, both from the Academia and from the Industry, and I can really recommend this course. Thank you for a great learning experience!
Monocl Strategy ServicesJonathan Holmén, Associate - Sweden - October 2016
This Valuation course is very useful and dynamic in terms of knowledge and skills. I particularly valued the step-by-step valuation process, the risk assessments in product valuation as well as the module on deal structuring and management. I highly recommend it!
ServierNatalia Baldina, Manager - Russia - October 2016
It is always a pleasure to meet real market professionals, with whom I can discuss and get valuable insight from. This course is of great help for my day-to-day work.
ServierAlexander Nozdrachev, Business Development Director - Russia - April 2016
Excellent overview of valuation of products & companies (in life sciences).
BioArctic NeuroscienceGunilla Osswald, CEO - Sweden - April 2016
As a CEO of a start-up that is currently raising money I found this valuation course just perfect!
Anaconda BioMedOfir Arad, CEO - Spain - April 2016
Truly excellent course to learn the fundamentals of company and product valuations in biotech!
AlacritaPriyaanka Nanduri, Consultant Analyst - United States - April 2016
The valuation course led by Dr. Patrik Frei was an excellent introduction to both product and company valuation, which required no detailed prior knowledge of the topic. The course covered in detail the major valuation methods and their relative benefits and challenges, which was both informative and interesting. Perhaps the most useful elements of the course were the group practical exercises where we could put the theory we had learned into practice. I highly recommend this concise and expertly delivered course to any executives venturing into the murky, yet essential, world of asset and company valuation!
EUSA PharmaBenjamin Owens, Business Development Director - United Kingdom - October 2015
A valuable experience, and also useful for newcomers in the field of valuation
ZambonDaniele Colombo, Pipeline Development & Science Intelligence - Italy - October 2015
Dr. Patrik Frei’s valuation course was first class. Patrik’s presentation style was natural and relaxed, with questions encouraged. The content was clear and easy to follow. The course notes and spreadsheet template provide permanent tools for business evaluation. Highly recommended!
Monitus ResearchDavid Salisbury, Managing Director - United Kingdom - March 2015
Very helpful for understanding the key elements, and nuances, of biotech company and product valuations.
Cellectar BiosciencesJ. Patrick Genn, Vice President Business Development - United States of America - March 2015
Definitely a great introduction course for inexperienced biotech people who are aiming to be part of a collaboration deal and want to become stronger in bargaining and to see what stands behind the proposed offer.
SotioJakub Jarolim, Strategy Analyst - Czech Republic - March 2015
This course really met my expectations and covered important grey areas. The learned topics will allow me to interact with other functions in my company and during deals and negotiations.
Sigma-TauMassimo Orlando, Head of International Marketing Intelligence - Italy - March 2015
The course fitted perfectly with my needs for knowledge in this specific area!
ProStrakanBas Sibeijn, General Manager - Germany - October 2014
A complex subject but explained very well by Patrik. It was interesting to see all the elements used in valuation.
Sterling IPGraham Golding, Valuation and Compliance Officer - UK - October 2014
This course was a beautiful experience! Nice to share and talk with Pharma/Biotech professionals from different companies.
Caixa Capital RiscGuillem Masferrer Bosch, Operations Analyst - Spain - October 2014
Thank you very much for this course! Patrik Frei's Valuation course is perfect for preliminary understanding of biotech product and company valuation.
JSC FarmakKateryna Arnaut, Business Development Manager - Ukraine - October 2014
Patrik Frei's Valuation course is very interesting and informative - Highly recommendable!
Wealth and Asset Management SolutionsValdo Petrino, Portfolio Manager - Switzerland - October 2014
Excellent summary of the principles of valuation. Great course overall!
JanssenAhmed Mohamed, New Business Development Manager - UK - March 2014
Patrik Frei demonstrated a lot of competence, even though the time was limited and the topic demanding.
CelonicRoland Meisel, Senior Director Business Development - Switzerland - March 2014
Very practical course for someone who has little experience in the area.
TecnifarTelma Faria Lapa Rodrigues Costa, Technical Director - Portugal - March 2014
This course was recommended to me by my colleague and this was indeed perfect on all dimensions: expert, course content, organization and audience. I rated this course top level on all parameters - congratulations!
AvexxinScott Woodward, Head of BD - Norway - October 2013
This course was to the point as an entry point to valuation methods. Perfect content.
AvexxinMikael Orum, CEO - Norway - March 2013
Very impressive course which gives, in short time, deep insightful information about the topic.
Planta-SolutionsAndreas von Planta, Owner - Switzerland - October 2012
This was an excellent, very well-explained introductory course. I learned a lot! Good way of presenting complex info, congratulations!
EuresearchSascha Hugentobler, Swiss National Contact Point for FP7 Health - Switzerland - October 2012
I enjoyed the workshop very much and appreciate the professional performance of the expert. This seminar helped me to understand better the valuation process.
Immune PharmaAnna Baran, Director Corporate Development - USA - March 2012
I found it very useful to participate and interact. I was already familiar with company valuation from the past, but seeing it in practice in a pharma-biotech setting, where the assumptions are so much more numerous and complex, was really an eye-opener. The material provided is also very helpful in my current role as a F&A Manager in Biotech.
arGEN-XMarc Moens, F&A Manager - Belgium - October 2011
A very good course that explains the complex process of valuation in a way that is easy to understand.